骨髓纤维化患者RAS通路突变的预后影响
该研究分析了三个国际中心723例原发和继发骨髓纤维化患者的16个基因二代测序数据,评估RAS通路突变的意义。N/KRAS突变见于6%患者,多为亚克隆,与白细胞增多、高突变负荷及分子高危突变相关,且与更短3年总生存和更高3年急性髓系白血病发生率相关。多因素Cox模型显示RAS突变与总生存下降相关,并构建了新评分预测总生存。
要点
- 骨髓纤维化患者中N/KRAS突变占6%,通常为亚克隆,中位VAF为20%。
- RAS突变与白细胞增多、高突变负荷及分子高危突变相关,提示侵袭性表型。
- RAS突变患者3年总生存更短(34% vs 58%),3年急性髓系白血病发生率更高(18% vs 11%)。
核心结论
- 骨髓纤维化患者中RAS通路突变与不良预后相关,识别RAS突变具有重要临床意义。
研究设计与样本
- 研究分析了三个国际中心723例原发和继发骨髓纤维化患者的16个基因二代测序数据,包括RAS通路基因。
主要发现
- N/KRAS变异存在于6%的患者中,相对于其他基因变异通常为亚克隆,中位VAF为20%。
- RAS变异与晚期骨髓纤维化特征相关,包括白细胞增多(p=0.02)、高体细胞突变负荷(p<0.01)和已确立的「分子高危」突变的存在。
- 伴有N/KRAS突变的骨髓纤维化患者3年总生存较短(34% vs 58%,p<0.001),3年急性髓系白血病发生率较高(18% vs 11%,p=0.03)。
- 在多因素Cox模型中,RAS突变与总生存下降相关(HR 1.93,p<0.001)。
- 研究创建了一个纳入RAS突变的新评分预测总生存,并在训练和验证队列中预测了总生存。
关键数值与推荐
- N/KRAS变异存在于6%的患者中,中位VAF为20%。
- RAS变异与白细胞增多相关(p=0.02),与高体细胞突变负荷相关(p<0.01)。
- 伴有N/KRAS突变患者3年总生存为34% vs 58%(p<0.001),3年急性髓系白血病发生率为18% vs 11%(p=0.03)。
- 多因素Cox模型中RAS突变与总生存下降相关(HR 1.93,p<0.001)。
临床怎么用
- 对骨髓纤维化患者应进行RAS通路基因检测以识别高危亚组。
- RAS突变可纳入预后评分系统辅助风险分层。
- 伴RAS突变的 intermediate/high-risk DIPSS 患者接受芦可替尼治疗的2年总生存相对未接受者无显著延长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF across three international centers and evaluated their significance. N/KRAS variants were present in 6% of patients and were typically sub-clonal (median VAF = 20%) relative to other genes variants. RAS variants were associated with advanced MF features including leukocytosis (p = 0.02), high somatic mutation burden (p < 0.01) and the presence of established "molecular high-risk" (MHR) mutations. MF patients with N/KRAS mutations had shorter 3-year overall survival (OS) (34% vs 58%, p < 0.001) and higher incidence of acute myeloid leukemia at 3 years (18% vs 11%, p = 0.03). In a multivariate Cox model, RAS mutations were associated with decreased OS (HR 1.93, p < 0.001). We created a novel score to predict OS incorporating RAS mutations, and it predicted OS across training and validation cohorts. Patients with intermediate risk/high-risk DIPSS with RAS mutations who received ruxolitinib had a nonsignificant longer 2-year OS relative to those who did not receive ruxolitinib. These data demonstrate the importance of identifying RAS mutations in MF patients.
引用
- Santos FPS, Getta B, Masarova L, et al. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2019. PMID: 31628430. doi:10.1038/s41375-019-0603-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。